Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran.
Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran.
Ann Diagn Pathol. 2020 Jun;46:151507. doi: 10.1016/j.anndiagpath.2020.151507. Epub 2020 Mar 13.
Prolactin receptor (PRLR) is a novel emerging prognostic biomarker in different cancers, especially in breast cancer. However, there is limited information about the association of PRLR expression and triple-negative breast cancers (TNBC) prognosis. In this study, 80 TNBC patients were evaluated for PRLR expression by immunohistochemistry. The correlation of PRLR expression with clinicopathological features, patient recurrence, and survival was investigated. PRLR expression was considered positive if >10% of tumor cells were stained. The Fisher's exact test was used to analyze PRLR expression relation with the clinicopathological parameters. Survival distribution was estimated by the Kaplan-Meier method. Positive immunoreactivity for PRLR was observed in 50 out of 80 (62%) specimens. Although expression of PRLR was associated with TNBC patients' stage, no-correlation was observed between its expression and tumor size, grade, lymph node status, and Ki-67 expression. In addition, patients with positive expression of PRLR exhibited lower recurrence (P = 0.0027) and higher overall survival (P = 0.0285) in comparison with negative expression group. In multivariate analyses, positive expression of PRLR was an independent prognostic marker for lower recurrence (P < 0.001) and higher overall survival (P < 0.001). Therefore, PRLR plays a crucial role in TNBC and has to be considered as an independent prognostic biomarker for TNBC patients.
催乳素受体（PRLR）是不同癌症中一种新出现的预后生物标志物，尤其在乳腺癌中。然而，关于 PRLR 表达与三阴性乳腺癌（TNBC）预后的相关性的信息有限。在这项研究中，通过免疫组织化学评估了 80 例 TNBC 患者的 PRLR 表达。研究了 PRLR 表达与临床病理特征、患者复发和生存的相关性。如果>10%的肿瘤细胞染色，则认为 PRLR 表达为阳性。Fisher 确切检验用于分析 PRLR 表达与临床病理参数的关系。生存分布通过 Kaplan-Meier 方法估计。在 80 例标本中，有 50 例（62%）观察到 PRLR 的阳性免疫反应。尽管 PRLR 的表达与 TNBC 患者的分期相关，但未观察到其表达与肿瘤大小、分级、淋巴结状态和 Ki-67 表达之间的相关性。此外，与 PRLR 表达阴性组相比，PRLR 表达阳性的患者复发率较低（P=0.0027），总生存率较高（P=0.0285）。在多变量分析中，PRLR 表达阳性是复发率降低（P<0.001）和总生存率升高（P<0.001）的独立预后标志物。因此，PRLR 在 TNBC 中发挥着关键作用，并且必须被视为 TNBC 患者的独立预后生物标志物。
